Expert Review of Vaccines最新文献_第6页

Vaccination policies for dentists and other dental professionals in Europe: a systematic report. 欧洲牙医和其他牙科专业人员的疫苗接种政策：一份系统报告。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-06-05 DOI: 10.1080/14760584.2025.2516254

Helena C Maltezou, Audrey Camilleri, Nuala Carney, Anna Chainier, Katrín Guðmundsdóttir, Erminija Guzaitienė, Charlotte Heuzé, Jörg Krainhöfner, Peter Kukolik, Mercedes Linninger, Jens Nagaba, Miguel Pavao, Harry-Sam Selikowitz, Nikolai Sharkov, Freddie Sloth-Lisbjerg, Roman Smucler, Marek Szewczyński, Brigitte van Dam, Luca Vettore, Lynn Woods, Oliver Zeyer, Ioannis Tzoutzas

{"title":"Vaccination policies for dentists and other dental professionals in Europe: a systematic report.","authors":"Helena C Maltezou, Audrey Camilleri, Nuala Carney, Anna Chainier, Katrín Guðmundsdóttir, Erminija Guzaitienė, Charlotte Heuzé, Jörg Krainhöfner, Peter Kukolik, Mercedes Linninger, Jens Nagaba, Miguel Pavao, Harry-Sam Selikowitz, Nikolai Sharkov, Freddie Sloth-Lisbjerg, Roman Smucler, Marek Szewczyński, Brigitte van Dam, Luca Vettore, Lynn Woods, Oliver Zeyer, Ioannis Tzoutzas","doi":"10.1080/14760584.2025.2516254","DOIUrl":"https://doi.org/10.1080/14760584.2025.2516254","url":null,"abstract":"Background: Dentists and other dental healthcare professionals (DHCP) are at increased risk for several vaccine-preventable diseases (VPDs). We studied vaccination policies for DHCP in Europe.Methods: The national dental associations and chambers of 31 European countries were invited to complete a structured form. The survey was conducted in 2023.Results: Vaccination policies for DHCP existed in all (21) participating countries. Vaccination policies against hepatitis B, COVID-19 and influenza existed in 20, 18, and 17 countries, respectively. Vaccination policies against measles, mumps, rubella, and varicella existed in 8, 7, 7, and 7 countries, respectively, and against diphtheria, tetanus, poliomyelitis, and pertussis in 5, 5, 4, and 2 countries, respectively. Vaccination policies against hepatitis A existed in 5 countries, against meningococcus C, meningococcus A, C, W, Y, and meningococcus B in 1, 2, and 2 countries, respectively, and against tuberculosis and pneumococcus in 4 countries each. Thirteen countries had mandatory vaccination policies.Conclusions: All participating countries had vaccination policies targeting DHCP, however there were significant differences in the number of vaccinations and the implementation frame (mandatory or voluntary vaccinations). Considering the recent outbreaks of VPDs in Europe, vaccination programs for DHCP should be evaluated and strengthened to promote safety in dental facilities.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunization information systems' implementation and characteristics across the world: a systematic review of the literature. 免疫信息系统在世界各地的实施和特点：文献的系统回顾。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-05-25 DOI: 10.1080/14760584.2025.2510338

Giacomo Pietro Vigezzi, Elena Maggioni, Laura Clavario, Lorenzo Clerico Mosina, Eleonora Raso, Corina Marjin, Andrea Parrini, Matteo Carbone, Simone Fugazza, Alberto Marchisio, Manuela Martella, Giansanto Mosconi, Giuseppina Lo Moro, Fabrizio Bert, Corrado De Vito, Roberta Siliquini, Anna Odone

{"title":"Immunization information systems' implementation and characteristics across the world: a systematic review of the literature.","authors":"Giacomo Pietro Vigezzi, Elena Maggioni, Laura Clavario, Lorenzo Clerico Mosina, Eleonora Raso, Corina Marjin, Andrea Parrini, Matteo Carbone, Simone Fugazza, Alberto Marchisio, Manuela Martella, Giansanto Mosconi, Giuseppina Lo Moro, Fabrizio Bert, Corrado De Vito, Roberta Siliquini, Anna Odone","doi":"10.1080/14760584.2025.2510338","DOIUrl":"https://doi.org/10.1080/14760584.2025.2510338","url":null,"abstract":"Introduction: Immunization Information Systems (IISs) are essential public health tools, supporting the management and analysis of vaccination data to aid clinical and strategic decision-making.Methods: Following PRISMA guidelines, this systematic review investigated global state and operational characteristics of IISs. A comprehensive search across multiple databases up to 6 June 2023, identified 2,612 articles, with 238 included.Results: A significant increase in IIS research was observed in recent years, with a strong preference (84.5%) for electronic immunization registries (EIRs). Notably, 36% of IISs operate at the national level, and 47.7% meet the U.S. CDC definition, 17.0% are interoperable with personal health records, and 11.7% provide direct access to vaccination data for vaccinees or their guardians. Other key features include automated reminder systems for recipients and providers (12.1%), near real-time or real-time data entry (11.0%), the inclusion of demographic and socioeconomic data (16.7%), and the capacity to document vaccine refusal or hesitancy (10.2%).Conclusions: IISs contribute to improving population-level surveillance of vaccine-preventable diseases. Persistent limitations related to data standardization, interoperability, and cost-effectiveness evaluation must be addressed. Strengthening these aspects is crucial to fully harness the potential of IISs in various healthcare settings, where enhanced vaccination tracking and targeting are most urgently needed.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary of responses to common misconceptions relating to updated COVID-19 mRNA vaccines. 对与更新的COVID-19 mRNA疫苗有关的常见误解的反应的简明语言总结。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-04-04 Epub Date: 2025-04-10 DOI: 10.1080/14760584.2025.2480300

George Kassianos, Ivan Aloysius

引用次数: 0

A plain language summary of the available safety data for the BNT162b2 COVID-19 vaccine: development, approval, and surveillance of use. BNT162b2 COVID-19疫苗现有安全性数据的简明语言摘要：开发、批准和使用监测。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-04-04 DOI: 10.1080/14760584.2025.2480282

Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Claudia Lindemann, Federico Mensa

引用次数: 0

Estimating the time required to reach HPV vaccination targets across Europe. 估算欧洲实现 HPV 疫苗接种目标所需的时间。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-09-13 DOI: 10.1080/14760584.2024.2402535

Ilias Gountas,Mohammed Aman,Deepak Alexander,Robert Hughes,Georgie Weston,Ugne Sabale

{"title":"Estimating the time required to reach HPV vaccination targets across Europe.","authors":"Ilias Gountas,Mohammed Aman,Deepak Alexander,Robert Hughes,Georgie Weston,Ugne Sabale","doi":"10.1080/14760584.2024.2402535","DOIUrl":"https://doi.org/10.1080/14760584.2024.2402535","url":null,"abstract":"BACKGROUNDCervical cancer (CC) is one of the most common causes of cancer-related deaths in women. The World Health Organization (WHO) has called for the CC elimination as a public health priority and has urged countries to achieve a 90% vaccine coverage rate of human papilloma virus (HPV) vaccination among 15-year-old girls by 2030.RESEARCH DESIGN AND METHODSRegression models were fitted to the WHO HPV vaccine coverage rate data to estimate when the 90% vaccine coverage rate target would be achieved in 22 European countries.RESULTSThe mean vaccine coverage rate of included countries was 62.2% (SD: 18.3). Nine countries (Iceland, Norway, Portugal, Ireland, Hungary, Spain, Sweden, Denmark, and Switzerland) are expected to achieve a 90% vaccine coverage rate by 2030. Six countries (Estonia, Cyprus, Netherlands, France, Germany, and Italy) are expected to reach a 90% vaccine coverage rate between 2030 and 2040 whereas seven countries (Belgium, Bulgaria, Finland, Latvia, Luxembourg, Malta, and Slovenia) are not expected to achieve the 90% vaccine coverage rate target by 2040.CONCLUSIONThe majority of European countries are not on track to achieve 90% vaccine coverage rate by 2030. To achieve this, a significant increase in the annual vaccine coverage rate growth rate is required.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"21 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines. 关于 Moderna, inc.COVID-19 疫苗的实际影响的描述性综述。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-09-13 DOI: 10.1080/14760584.2024.2402955

Mary Bausch-Jurken,Rachel S Dawson,Francesca Ceddia,Veronica Urdaneta,Morgan A Marks,Yohei Doi

{"title":"A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines.","authors":"Mary Bausch-Jurken,Rachel S Dawson,Francesca Ceddia,Veronica Urdaneta,Morgan A Marks,Yohei Doi","doi":"10.1080/14760584.2024.2402955","DOIUrl":"https://doi.org/10.1080/14760584.2024.2402955","url":null,"abstract":"INTRODUCTIONSince the original COVID-19 vaccines were developed, abundant clinical trial and real-world evidence evaluating the efficacy, effectiveness, and safety of COVID-19 vaccines has been collected. Knowledge of the relative benefits and risks of COVID-19 vaccines is essential for building trust within target populations, ensuring they remain effectively and safely protected against an enduring infectious threat.AREAS COVEREDThis descriptive review discusses the benefits and risks associated with marketed Moderna, Inc. mRNA-based COVID-19 vaccines, focusing on their real-world effectiveness and safety profiles in various age groups. Adverse events of interest and potential benefits of vaccination are reviewed, including reduced risk for severe COVID-19 and long-term health outcomes, reduced economic and societal costs, and reduced risk for SARS-CoV-2 transmission.EXPERT OPINIONPost-marketing safety and real-world data for Moderna, Inc. COVID-19 mRNA vaccines strongly support a positive benefit - risk profile favoring vaccination across all age groups. Although COVID-19 is no longer considered a global health pandemic, health risks associated with SARS-CoV-2 infection remain high. Concerted efforts are required to engage communities and maintain protection through vaccination. Continued surveillance of emerging variants and monitoring of vaccine safety and effectiveness are crucial for ensuring sustained protection against SARS-CoV-2.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"81 5 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024. 单克隆抗体和其他生物治疗患者的疫苗接种策略：根据截至 2024 年 1 月的 EMA 授权进行的最新全面审查。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-09-11 DOI: 10.1080/14760584.2024.2401839

Mario Rivera-Izquierdo,Arturo Morales-Portillo,Inmaculada Guerrero-Fernández de Alba,Nicolás Francisco Fernández-Martínez,Joan Antoni Schoenenberger-Arnaiz,José Luis Barranco-Quintana,Carmen Valero-Ubierna

{"title":"Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024.","authors":"Mario Rivera-Izquierdo,Arturo Morales-Portillo,Inmaculada Guerrero-Fernández de Alba,Nicolás Francisco Fernández-Martínez,Joan Antoni Schoenenberger-Arnaiz,José Luis Barranco-Quintana,Carmen Valero-Ubierna","doi":"10.1080/14760584.2024.2401839","DOIUrl":"https://doi.org/10.1080/14760584.2024.2401839","url":null,"abstract":"INTRODUCTIONMonoclonal antibodies (mAbs) and other biological agents are being increasingly approved in the last years with very different indications. Their highly heterogeneous immunosuppressive effects, mechanisms of action and pharmacokinetics require comprehensive individualized vaccination schedules.AREAS COVEREDVaccination for immunocompromised patients. Prevention and treatment with mAbs and other biological therapies.EXPERT OPINIONCurrent recommendations on vaccine schedules for patients under mAbs or other biological treatments are based on expert opinions and are not individualized according to each vaccine and treatment. No studies are focusing on the high heterogeneity of these agents, that are exponentially developed and used for many different indications. Recent paradigm changes in vaccine development (boosted by the COVID-19 pandemic) and in the mAbs use for prophylactic purposes (changing 'vaccination' by 'immunization' schedules) has been witnessed in the last years. We aimed at collecting all mAbs used for treatment or prevention, approved as of 1 January 2024, by the EMA. Based on available data on mAbs and vaccines, we propose a comprehensive guide for personalizing vaccination. Recent vaccine developments and current population strategies (e.g. zoster vaccination or prophylactic nirsevimab) are discussed. This review aims to be a practical guideline for professionals working in vaccine consultations for immunosuppressed patients.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"45 1","pages":""},"PeriodicalIF":6.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142195989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-neuraminidase immunity in the combat against influenza 抗神经氨酸酶免疫在流感防治中的作用

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-04-17 DOI: 10.1080/14760584.2024.2343689

Xiaojian Zhang, Ted M. Ross

引用次数: 0

Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary 开发适应变种的 COVID-19 疫苗，提高对 Omicron 和其他最新变种的保护：浅显易懂的摘要

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-04-05 DOI: 10.1080/14760584.2024.2320858

Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa

引用次数: 0

Multiple antigen presenting system (MAPS): state of the art and potential applications. 多重抗原递呈系统（MAPS）：最新技术和潜在应用。

IF 6.2 3区医学

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-01-08 DOI: 10.1080/14760584.2023.2299384

Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer

{"title":"Multiple antigen presenting system (MAPS): state of the art and potential applications.","authors":"Richard Malley, Ying-Jie Lu, Shite Sebastian, Fan Zhang, David O Willer","doi":"10.1080/14760584.2023.2299384","DOIUrl":"10.1080/14760584.2023.2299384","url":null,"abstract":"Introduction: Technological innovations have been instrumental in advancing vaccine design and protective benefit. Improvements in the safety, tolerability, and efficacy/effectiveness profiles have profoundly reduced vaccine-preventable global disease morbidity and mortality. Here we present an original vaccine platform, the Multiple Antigen Presenting System (MAPS), that relies on high-affinity interactions between a biotinylated polysaccharide (PS) and rhizavidin-fused pathogen-specific proteins. MAPS allows for flexible combinations of various PS and protein components.Areas covered: This narrative review summarizes the underlying principles of MAPS and describes its applications for vaccine design against bacterial and viral pathogens in non-clinical and clinical settings.Expert opinion: The utilization of high-affinity non-covalent biotin-rhizavidin interactions in MAPS allows for combining multiple PS and disease-specific protein antigens in a single vaccine. The modular design enables a simplified exchange of vaccine components. Published studies indicate that MAPS technology may support enhanced immunogenic breadth (covering more serotypes, inducing B- and T-cell responses) beyond that which may be elicited via PS- or protein-based conjugate vaccines. Importantly, a more detailed characterization of MAPS-based candidate vaccines is warranted, especially in clinical studies. It is anticipated that MAPS-based vaccines could be adapted and leveraged across numerous diseases of global public health importance.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"196-204"},"PeriodicalIF":6.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0